Substance / Medication

Fluoxetine hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Gender based response to fluoxetine hydrochloride medication in endogenous depression.
Bano Samina, Akhter Saima, Afridi Muhammad Iqbal · J Coll Physicians Surg Pak · 2004
PMID: 15228850Observational
[Fluoxetine hydrochloride ameliorates symptoms of hepatic myelopathy: a case report].
Zhang J J, Gao H R · Zhonghua Gan Zang Bing Za Zhi · 2024
PMID: 39623579Case Report
Pleural fluid and serum eosinophilia: association with fluoxetine hydrochloride.
Behnia M, Dowdeswell I, Vakili S · South Med J · 2000
PMID: 10881782Case Report
Evaluation of caffeic acid fenethyl ester in testicular damage caused by fluoxetine hydrochloride in rats: effects of fluoxetine hydrochloride on testes.
Demiray Asoglu Zehra, Balli Ebru, Bayrak Gülsen et al. · Naunyn Schmiedebergs Arch Pharmacol · 2025
PMID: 41389347Other
Clinical effect of acupuncture at ghost points combined with fluoxetine hydrochloride on mild-to-moderate depression.
Wang Yi, Lu Qun, Penpat Ittipalanukul et al. · World J Psychiatry · 2024
PMID: 38984332OtherFull text (PMC)
Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection.
Khater Shaymaa Elsayed, El-Khouly Ahmed, Abdel-Bar Hend Mohamed et al. · Int J Pharm · 2021
PMID: 34416332OtherFull text (PMC)
andevaluation of taste-masked orodispersible tablets of fluoxetine hydrochloride for the treatment of depression.
Marzouk Maha A, Osman Dina A, Mohamed Omnia S · Drug Dev Ind Pharm · 2021
PMID: 33826435Other
Clinical serum metabolomics study on fluoxetine hydrochloride for depression.
Shen Dandan, Zhao Huan, Gao Shan et al. · Neurosci Lett · 2021
PMID: 33352278Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Fluoxetine hydrochloride (substance)
SNOMED CT
75115009
UMLS CUI
C0733380

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.